Zim Laboratories Ltd. (IN:ZIMLAB)
:ZIMLAB
Want to see IN:ZIMLAB full AI Analyst Report?
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹126.95
Previous CloseN/A
Volume52.11K
Average Volume (3M)6.28K
Market Cap
₹4.62B
Enterprise Value₹5.79B
Total Cash (Recent Filing)₹50.12M
Total Debt (Recent Filing)₹1.23B
Price to Earnings (P/E)20.0
Beta1.10
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.90
Shares Outstanding53,549,038
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.62
Price to Sales (P/S)1.09
P/FCF Ratio1.15K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Gross And Operating MarginsImproved gross margins and stable EBIT/EBITDA margins indicate durable cost control and operational efficiency. This supports consistent operating profitability, resilience to input-cost shocks, and the ability to reinvest in products and registrations over the medium term.
Improving Operating Cash FlowA notable improvement in operating cash flow strengthens liquidity and funds working capital and routine investments from internal sources. Over 2-6 months this reduces reliance on external financing and supports execution of product supply and export programs.
Healthy Equity Position And Manageable LeverageAn improving equity ratio and a manageable debt profile provide balance-sheet resilience. This structural strength gives capacity to absorb shocks, support regulatory registrations or capex, and pursue strategic partnerships without immediate financing stress.
Bears Say
Decline In Net Profit MarginA falling net profit margin implies weaker conversion of sales into earnings, pressuring return metrics and long-term profitability. If sustained, it undermines retained earnings growth, limits capacity for dividend or strategic investments, and raises sensitivity to cost or pricing shifts.
Low Free Cash Flow Due To High CapexPersistently low free cash flow from heavy capex reduces the firm's ability to return cash, pay down debt, or fund opportunistic investments. Over the medium term this can necessitate external funding and constrain flexibility if capex fails to deliver timely returns.
Rising Leverage TrendAn upward trend in leverage, even from manageable levels, erodes financial flexibility and raises interest-cost exposure. If margins or cash conversion weaken, elevated leverage heightens refinancing and solvency risks, limiting strategic options during downturns.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹126.95 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹4.62B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is May 14, 2026 which is in 15 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on Feb 11, 2026. The company reported ₹0.902 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.902.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 53,549,038 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of ₹0.902 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.719%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.
Technical Analysis
Albert David Ltd
―
Lyka Labs Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―